Lv1
48 积分 2021-03-04 加入
Sintilimab plus bevacizumab biosimilar IBI305 and chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): first interim results from a randomised, double-blind, multicentre, phase 3 trial
8小时前
待确认
Draft Document for Public Consultation: 28 iCARDIO Alliance Global Implementation Guidelines 29 on Obesity Management 2025
9天前
已完结
Design of a Fc-engineered tetravalent bispecific antibody targeting PD-1 and VEGF with cooperative biological effects
8个月前
已关闭
Design of a Fc-engineered tetravalent bispecific antibody targeting PD-1 and VEGF with cooperative biological effects
8个月前
已完结
Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease
8个月前
已完结
Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease
8个月前
已完结
Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial
11个月前
已完结
Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial
11个月前
已完结
Phase 1a dose escalation study of ivonescimab (AK112/SMT112), an anti-PD-1/VEGF-A bispecific antibody, in patients with advanced solid tumors
11个月前
已关闭
皖公网安备34019202002308
